Table 3.
Bleeding complications during study treatment of older (≥60 years) medical patients randomised to the anticoagulant fondaparinux or placebo
Bleeding complication | Fondaparinux group (n=425) | Placebo group (n=414) |
---|---|---|
Major bleeding: | ||
Fatal | 0 | 0 |
Requiring surgical intervention | 0 | 0 |
In a critical location | 0 | 0 |
Overt bleeding plus a decrease in haemoglobin concentration ≥20 g/L (<48 hours) or transfusion of ≥2 units | 1 | 1 |
Total No (%) | 1 (0.2) | 1 (0.2) |
Minor bleeding | 11 (2.6) | 4 (1.0) |